danger, will robinson, page-4

This Phase III result is indeed a good one. Of course it it hard for the market to put a premium on BTA because Laninamivir will only be submitted in Japan in March 2010 then you wait at most 18months for the approval. So we are looking at late 2011 market launch??? The US market will take a while since they have to do a phase III trial plus they have to look for a partner. So we can estimate the best case scenario in US is 2013? If you can wait for a few years then this is a real value company.

The RSV result was obviously held off. How can they get 2 results at the same time?

I believe at this stage people will be more focusing on royalties in the next quarter rather than Laninamivir.